- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03349073
An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
November 17, 2022 updated by: Taivex Therapeutics Corporation
An Extension Study of T-1101 (Tosylate) Administered Orally to Patients With Advanced Refractory Solid Tumors
T-1101 is a novel anti-cancer agent being developed by Taivex Therapeutics Corporation, and is being studied in a phase I dose escalation trial, protocol TAI-001.
That trial's primary aim is to study the safety and tolerability of T-1101 (Tosylate) in subjects with advanced refractory solid tumors, and provides for a maximum of 2 cycles of treatment.
At the end of 2 cycles of treatment, it is likely that some patients will be continuing to receive clinical benefit from T-1101 (Tosylate).
The intention of this program is to enable these patients to continue to receive T-1101 (Tosylate) at the discretion of the principal investigators and Taivex Therapeutics Corporation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taichung City, Taiwan
- China Medical University Hospital
-
Tainan, Taiwan, 704
- National Cheng Kung University (NCKU) Hospital
-
Taipei, Taiwan
- National Taiwan University Hospital
-
Taipei, Taiwan, 105
- Taipei Medical University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with advanced malignancy who are receiving T-1101 (Tosylate) in a previous Taivex Therapeutics Corp. sponsored study that has reached its endpoint, and who are, in the opinion of the investigator and/or sponsor, expected to continue to have an overall positive benefit/risk from continuing treatment.
- Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation, including the 30 days period after last study drug dosing.
- Women of childbearing potential who have a negative pregnancy test within 7 days of the first dose of T-1101 (Tosylate) in this long term extension trial.
- Patients who have completed the End of Study assessments in their originating study. Every effort should be made to conduct the End of Study visit such that the patient does not have any interruption in T-1101 (Tosylate) dosing.
- Signed and dated informed consent document indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrollment.
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
Exclusion Criteria:
- Any medical condition that, in the opinion of the investigator and/or sponsor, could jeopardize the safety of the patient.
- Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy).
- Progressive or untreated metastatic brain or meningeal tumors.
- Pregnancy or breastfeeding. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. Female patients must be surgically sterile or be postmenopausal, or must agree to the use of highly effective contraception during the period of therapy. Highly effective method of birth control is defined as one that results in a low failure rate (i.e. less than 1 percent per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, intra-uterine devices (IUDs), sexual abstinence, or a vasectomized partner.
- Substance abuse, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: T-1101 (Tosylate)
|
T-1101 (Tosylate) powder in bottle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical Tumor Response of T-1101 (Tosylate) in Participants with Advanced Cancers Categorization of response based on RECIST 1.1.
Time Frame: Up to 2 years
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 14, 2017
Primary Completion (ACTUAL)
June 24, 2019
Study Completion (ACTUAL)
June 24, 2019
Study Registration Dates
First Submitted
November 17, 2017
First Submitted That Met QC Criteria
November 17, 2017
First Posted (ACTUAL)
November 21, 2017
Study Record Updates
Last Update Posted (ACTUAL)
November 18, 2022
Last Update Submitted That Met QC Criteria
November 17, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAI-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Refractory Solid Tumors
-
OncoMed Pharmaceuticals, Inc.CompletedRefractory Solid Tumors | Advanced Relapsed TumorsUnited States
-
Taivex Therapeutics CorporationActive, not recruitingAdvanced Refractory Solid TumorsTaiwan
-
Sunshine Lake Pharma Co., Ltd.CompletedAdvanced Refractory Solid TumorsChina
-
National OncoVentureChong Kun Dang PharmaceuticalUnknownAdvanced Refractory Solid TumorsKorea, Republic of
-
Piramal Enterprises LimitedSuspendedAdvanced Refractory Solid TumorsUnited States, India
-
Piramal Enterprises LimitedSuspendedAdvanced Refractory Solid TumorsUnited States, India
-
Second Affiliated Hospital of Soochow UniversityRecruitingAdvanced Refractory Solid TumorsChina
-
CStone PharmaceuticalsBayerCompletedAdvanced Refractory Solid TumorsAustralia
-
Taivex Therapeutics CorporationTerminatedAdvanced Refractory Solid TumorsTaiwan
-
Shanghai Pudong HospitalUTC Therapeutics Inc.WithdrawnMesothelin-positive Advanced Refractory Solid TumorsChina
Clinical Trials on T-1101 (Tosylate)
-
Taivex Therapeutics CorporationTerminatedAdvanced Refractory Solid TumorsTaiwan
-
Taivex Therapeutics CorporationActive, not recruitingAdvanced Refractory Solid TumorsTaiwan
-
National Cancer Institute (NCI)WithdrawnLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin LymphomaUnited States
-
Chimeric TherapeuticsRecruitingGlioblastoma Multiforme of BrainUnited States
-
Daiichi Sankyo Co., Ltd.Active, not recruitingAdult T-cell Leukemia/LymphomaJapan
-
New York State Psychiatric InstituteIntra-Cellular Therapies, Inc.Terminated
-
The Lymphoma Academic Research OrganisationDaiichi SankyoActive, not recruitingStudy of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell LymphomaLymphoma, B-CellFrance, Belgium
-
Cleave Therapeutics, Inc.CompletedMyelodysplastic Syndromes | Acute Myeloid Leukemia, in RelapseUnited States, Australia
-
Daiichi SankyoRecruitingAdvanced Solid TumorUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Completed